Free Float 82,84 %
Shares Float 57,44 M
Shares Outstanding 69,34 M
QUANTUM GENOMICS EO -,40
Share · FR0011648971 · A1XAEB (XPAR)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of QUANTUM GENOMICS EO -,40
No Price
Share Float & Liquidity
Company Profile for QUANTUM GENOMICS EO -,40 Share
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
Company Data
Name QUANTUM GENOMICS EO -,40
Company Quantum Genomics S.A.
Website
https://www.quantum-genomics.com
Primary Exchange 
Paris
Paris
WKN A1XAEB
ISIN FR0011648971
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mathieu Bigois
Country France
Currency EUR
Employees 0,0 T
Address 33 rue Marbeuf, 75008 Paris
IPO Date 2010-05-28
Stock Splits
| Date | Split |
|---|---|
| 13.12.2013 | 1:18 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | QNNTF |
| Frankfurt | 2QG.F |
| Paris | ALQGC.PA |
More Shares
Investors who hold QUANTUM GENOMICS EO -,40 also have the following shares in their portfolio:
